Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide

Thrombosis Research

Volumn 86, Issue 1, 1997, Pages 1-36

  Walenga, Jeanine M ^a   Jeske, Walter P ^a   Bara, Lucienne ^b   Samama, Meyer M ^b   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b HÔTEL DIEU   (France)

Author keywords

Antithrombin; Antithrombotic; Factor Xa; Heparin; Pentasaccharide

Indexed keywords

HEPARIN; PENTASACCHARIDE;

ACETYLATION; CHEMICAL MODIFICATION; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME DEGRADATION; NOTE; PRIORITY JOURNAL; PROTEIN FAMILY; STRUCTURE ACTIVITY RELATION; SULFATION;

EID: 0030952743     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00042-X     Document Type: Article

References (141)

1. CASU, B. Methods of structural analysis. In: Heparin: Chemical and Biological Properties, Clinical Applications. D.A. Lane and U. Lindahl (eds.), pp. 25-50, Edward Arnold, London (1989).
2. ABILDGAARD U. Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis. Scand J Clin Lab Invest. 21:1968;89-91.
3. ANDERSSON L.O., BARROWCLIFFE T.W., HOLMER E., JOHNSON E.A., SIMS G.E.C. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res. 9:1976;575-583.
4. HÖÖK M., BJÖRK I., HOPWOOD J., LINDAHL U. Anticoagulant activity of heparin: Separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Lett. 66:1976;90-93.
5. LAM L.H., SILBERT J.E., ROSENBERG R.D. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun. 69:1976;570-577.
6. HOLMER E., KURACHI K., SÖDERSTRÖM G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J. 193:1981;395-400.
7. LAURENT T.C., TENGBLAD A., THUNBERG L., HÖÖ M., LINDAHL U. The molecular weight dependence of the anticoagulant activity of heparin. Biochem J. 175:1978;691-701.
8. OOSTA G.M., GARDNER W.T., BEELER D.L., ROSENBERG R.D. Multiple functional domains of the heparin molecule. Proc Natl Acad Sci USA. 78:1981;829-833.
9. BARROWCLIFFE, T.W., JOHNSON, E.A., EGGLETON, C.A., KEMBALL-COOK, G. and THOMAS, D.P. Anticoagulant activities of high and low molecular weight heparin fractions. Br J Haematol 41, 573-83, 1979.
10. CHOAY J., LORMEAU J.C., PETITOU M., SINÄY P., CASU B., ORESTE P., TORRI G., GATTI G. Anti-Xa active heparin oligosaccharides. Thromb Res. 18(3-4):1980;573-578.
11. CARTER C.J., KELTON J.G., HIRSH J., GENT M. Relationship between the anti-thrombotic and anticoagulant effects of low molecular weight heparin. Thromb Res. 21:1981;169-174.
12. HOLMER E., MATTSSON C., NILSSON S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res. 25:1982;475-485.
13. OCKELFORD P.A., CARTER C.J., MITCHELL L., HIRSH J. Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction. Thromb Res. 28:1982;401-409.
14. THOMAS D.P., MERTON R.E., LEWIS W.E., BARROWCLIFFE T.W. Studies in man and experimental animals of a low molecular weight heparin fraction. Thromb Haemost. 45:1981;214-218.
15. THOMAS D.P., MERTON R.E., BARROWCLIFFE T.W., THUNBERG L., LINDAHL U. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. Thromb Haemost. 47:1982;244-248.
16. CHOAY J., LORMEAU J.C., PETITOU M., SINÄY P., FAREED J. Structural studies on a biologically active hexasaccharide obtained from heparin. Ann NY Acad Sci. 370:1981;644-649.
17. THUNBERG L., BÄCKSTRÖM G., LINDAHL U. Further characterization of the antithrombin-binding sequence in heparin. Carbohydr Res. 100:1982;393-410.
18. LINDAHL U., BÄCKSTRÖM G., HOOK M., THUNBERG L., FRANSSON L.A., LINKER A. Structure of the antithrombin-binding site of heparin. Proc Natl Acad Sci USA. 76:1979;3198-3202.
19. CHOAY J., PETITOU M., LORMEAU J.C., SINÄY P., CASU B., GATTI G. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Acta. 116:1983;492-499.
20. ROSENBERG R.D., LAM L. Correlation between structure and function of heparin. Proc Natl Acad Sci USA. 76:1979;1218-1222.
21. SINÄY P., JACQUINET J.E., PETITOU M., DUCHAUSSOY P., LEDERMAN I., CHOAY J., TORRI G. Total synthesis of a heparin pentasaccharide fragment having high affinity for antithrombin III. Carbohydr Res. 132:1984;C5-C9.
22. PETITOU M., DUCHAUSSOY P., LEDERMAN I., CHOAY J., SINÄY P., JACQUINET J.C., TORRI G. Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide 0-(2-deoxy-2-sulfamido-6-O-sulfo-alpha-D-glucopyranosyl)-1->4)-0-(beta-D- glucopyranosyluronic acid)-(1->4)-0-(2-deoxy-2-sulfamido-3, 6-di-0-sulfo-alpha-D-glucopyranosyl)-(1->4)-0-(2-O-sulfo-alpha- L-idopyranosyluronic acid)-(1->4)-2-deoxy-2-sulfamido-6-O-sulfo-D-glucopyranose decasodium salt, a heparin fragment having high affinity for antithrombin III. Carbohydr Res. 147:1986;221-236.
23. ATHA D.H., LORMEAU J.C., PETITOU M., ROSENBERG R.D., CHOAY J. Contribution of monosaccharide residues in heparin binding to antithrombin III. Biochemistry. 24:1985;6723-6729.
24. TORRI G., CASU B., GATTI G., PETITOU M., CHOAY J., JACQUINET J.C. Mono- and bidimensional 500 MHZ proton NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: Evidence for conformational peculiarity of the sulfated iduronate residue. Biochem Biophys Res Commun. 128:1985;134-140.
25. LINDAHL U., BÄCKSTRÖM G., THUNBERG L. The antithrombin-binding sequence in heparin. Identification of an essential 6-0 sulfate group. J Biol Chem. 258:1983;9826-9830.
26. RIESENFELD J., THUNBERG L., HÖÖK M., LINDAHL U. The antithrombin-binding sequence of heparin. Location of essential N-sulfate groups. J Biol Chem. 256:1981;2389-2394.
27. PETITOU M., DUCHAUSSOY P., LEDERMAN I., CHOAY J., SINÄY P., JACQUINET J.C., TORRI G. Synthesis of heparin fragments: A α-methyl alpha-pentaoside with high affinity for antithrombin III. Carbohydr Res. 167:1987;67-75.
28. PETITOU M., LORMEAU J.C., CHOAY J. A new synthetic pentasaccharide with increased anti-factor Xa activity: Possible role for anionic clusters in the interaction of heparin and antithrombin III. Semin Thromb Hemost. 17(2):1991;143-146.
29. PETITOU M., VAN BOECKEL C.A.A. Chemical synthesis of heparin fragments and analogues. Prog Chem Org Nat Prod. 60:1992;143-210.
30. RAGAZZI M., FERRO D.R. Conformation of the pentasaccharide corresponding to the binding site of heparin to antithrombin-III. Carbohyr Res. 165:1987;C1-C5.
31. RAGAZZI M., FERRO D.R. Conformation of the pentasaccharide corresponding to the binding site of heparin for antithrombin III. Carbohydr Res. 195:1990;169-185.
32. CASU B., ORESTE P., TORRI G., ZOPPETTI G., CHOAY J., LORMEAU J.C., PETITOU M., SINÄY P. The structure of heparin oligosaccharide fragments with anti-factor Xa activity containing the minimal antithrombin III-binding sequence. Biochem J. 197:1981;599-609.
33. 1H-n.m.r. spectroscopy of the binding of a synthetic, high-affinity heparin pentasaccharide to human antithrombin III. Carbohydr Res. 185:1989;69-76.
34. PETITOU M. Synthetic heparin fragments: new and efficient tools for the study of heparin and its interactions. Nouv Rev Fr Hematol. 26:1984;221-226.
35. PETITOU M., DUCHAUSSOY P., LEDERMAN I., CHOAY J. Binding of heparin to antithrombin III: A chemical proof of the critical role played by a 3-sulfated 2-amino-2-deoxy-D-glucose residue. Carbohydr Res. 179:1988;163-172.
36. WALENGA, J.M. Doctoral thesis: Factor Xa Inhibition in Mediating Antithrombotic Actions: Application of a Synthetic Heparin Pentasaccharide. Mention tres bien. Universite Pierre et Marie Curie, Paris VI, Paris, France, June 1987.
37. WALENGA J.M., PETITOU M., SAMAMA M., FAREED J., CHOAY J. Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activity. Thromb Res. 52:1988;553-563.
38. VAN BOECKEL C.A.A., BEETZ T., VOS J.N., DE JONG A.J.M., VAN AELST S.F., VAN DEN BOSCH R.H., MERTENS J.M.R., VAN DER VLUGT F.A. Synthesis of a pentasaccharide corresponding to the antithrombin III binding fragment of heparin. J Carbohydr Chem. 4:1985;293-321.
39. PETITOU M., LORMEAU J.C., CHOAY J. A new synthetic pentasaccharide with increased anti-factor Xa activity: Possible role for anionic clusters in the interaction of heparin and antithrombin III. Semin Thromb Res. 19(2):1993;143-146.
40. VISSER A., BUITING M.T., VAN DINTHER T.G., VAN BOECKEL C.A.A., GROOTENHUIS P.G., MEULEMAN D.G. The AT-III binding affinities of a series of synthetic pentasaccharide analogues. Thromb Haemost. 65:1991;1296.
41. MEULEMAN D.G., HOBBELEN P.M.J., VAN DINTHER T.G., VOGEL G.M.T., VAN BOECKEL C.A.A., MOELKER H.C.T. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: Discovery of compounds with a longer duration of action than of the natural pentasaccharide. Semin Thromb Hemost. 17(1):1991;112-117.
42. VAN AMSTERDAM R.G.M., VOGEL G.M.T., VISSER A., KOP W.J., BUITING M.T., MEULEMAN D.G. Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin. Prediction of in vivo residence times. Arterioscler Thromb Vasc Biol. 15:1995;495-503.
43. HERAULT J.P., BARZU T., CREPON B., BERNAT A., LORMEAU J.C., HERBERT J.M., PETITOU M. Biochemical and pharmacological properties of O-sulfated, O-methylated analogues of the natural pentasaccharide. Thromb Haemost. 73:1995;1321.
44. HERBERT J.M., HERAULT J.P., BARZU T., BERNAT A., LORMEAU J.C., PETITOU M. Biochemical and pharmacological properties of SANORG 32701, a potent analogue of the 'natural pentasaccharide.'. Thromb Haemost. 73:1995;1321.
45. CHANDRA T., STACKHOUSE R., KIDD V.J., WOO S.L.C. Isolation and sequence characterization of a cDNA clone of human antithrombin III. Proc Natl Acad Sci USA. 80:1983;1845-1848.
46. CONARD J., BROSSTAD F., LARSEN M.L., SAMAMA M., ABILDGAARD U. Molar antithrombin concentration in normal human plasma. Haemostasis. 13:1983;363-368.
47. ROSENBERG R.D., DAMUS P.S. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. 248:1973;6490-6505.
48. DAMUS P.S., HICKS M., ROSENBERG R.D. Anticoagulant action of heparin. Nature. 246:1973;355-357.
49. JORDAN R.E., OOSTA G.M., GARDNER W.T., ROSENBERG R.D. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem. 255:1980;10081-10090.
50. BRENNAN S.O., BORG J.Y., GEORGE P.M., SORIA C., SORIA J., CAEN J., CARRELL R.W. New carbohydrate site in mutant antithrombin (7ILE-ASN) with decreased heparin affinity. FEBS Lett. 237:1988;118-122.
51. OLSON S.T., BJÖRK I., SHEFFER R., CRAIG P.A., SHORE J.D., CHOAY J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. J Biol Chem. 267:1992;12528-12538.
52. BJÖRK, I. and DANIELSSON, A. Antithrombin and related inhibitors of coagulation proteinases. In: Proteinase Inhibitors. A.J. Barrett and G.S. Salvesen (eds.), pp. 489-513, Elsevier, Amsterdam, The Netherlands (1986).
53. PETERSON C.B., BLACKBURN M.N. Antithrombin conformation and the catalytic role of heparin II. Is the heparin-induced conformational change in antithrombin required for rapid inactivation of thrombin. J Biol Chem. 262:1987;7559-7566.
54. NESHEIM M., BLACKBURN M.H., LAWLER C.M., MANN K.G. Dependence of antithrombin III and thrombin binding stoichiometries and catalytic activity on the molecular weight of affinity purified heparin. J Biol Chem. 261:1986;3214-3221.
55. HOYLAERTS M., OWEN W.G., COLLEN D. Involvement of heparin chain length in the heparin catalyzed inhibition of thrombin by antithrombin III. J Biol Chem. 259:1984;5670-5677.
56. GRIFFITH M.J. The heparin-enhanced antithrombin III/thrombin reaction is saturable with respect to both thrombin and antithrombin III. J Biol Chem. 257:1982;13899-13902.
57. GRIFFITH M.J., NOYES L.M., CHURCH F.C. Reactive site peptides structural similarity between heparin cofactor II and antithrombin III. J Biol Chem. 260:1985;2218-2225.
58. LORMEAU J.C., HERAULT J.P. The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to AT-mediated neutralization of factor Xa. Thromb Haemost. 74:1995;1474-1477.
59. KAISER B., HOPPENSTEADT D., JESKE W., WALENGA J.M., FAREED J., SAMAMA M. Heparin cofactor II interactions with heparin pentasaccharide are minimal to mediate its antithrombotic actions. Thromb Haemost. 69:1993;1111.
60. WALENGA J.M., FAREED J. Preliminary biochemical and pharmacological studies on a chemically synthesized pentasaccharide. Semin Thromb Hemost. 11:1985;89-99.
61. BENDAYAN P., BOCCALON H., DUPOUY D., BONEU B. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Thromb Haemost. 71:1994;576-580.
62. BENDETOWICZ A.V., BARA L., SAMAMA M.M. The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma. Thromb Res. 58:1990;445-454.
63. HEMKER H.C., CHOAY J., BÉGUIN S. Free factor Xa is on the main pathway of thrombin generation in clotting plasma. Biochem Biophys Acta. 992:1989;409-411.
64. EISENBERG P.R., SIEGEL J.E., ABENDSCHEIN D.R., MILETICH J.P. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest. 91:1993;1877-1883.
65. CADROY Y., HANSON S.R., HARKER L.A. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in nonhuman primates. Thromb Haemost. 70:1993;631-635.
66. HÉRAULT J.P., PFLIEGER A.M., SAVI P., LORMEAU J.C., HOFFMAN P., BERNAT A., HERBERT J.M. Comparative effects of two factor Xa inhibitors on prothrombinase assembled in different environments. Haemostasis. 26:1996;S3.
67. WALENGA J.M., PETITOU M., LORMEAU J.C., SAMAMA M., FAREED J., CHOAY J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res. 46:1987;187-198.
68. WALENGA J.M., BARA L., HOPPENSTEADT D., CHOAY J., FAREED J., SAMAMA M. AT III as a rate limiting factor for the measurement of pentasaccharide in laboratory assays. Thromb Haemost. 65:1991;1314.
69. BONEU B., NECCIARI J., CARIOU R., SIÉ P., GABAIG A.M., KIEFFER G., DICKINSON J., LAMOND G., MOELKER H., MANT T., MAGNANI H. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb Haemost. 74:1995;1468-1473.
70. WALENGA J.M., BARA L., PETITOU M., SAMAMA M., FAREED J., CHOAY J. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Thromb Res. 51:1988;23-33.
71. DOL F., GAICH C., PETITOU M., BONEU B., CARANOBE C., BERNAT A., SAINTE MARIE M., HERBERT J.M. The antithrombotic activity of synthetic pentasaccharides and fraxiparine is closely correlated with their respective ability to alter thromboplastin-triggered thrombin generation ex vivo. Thromb Haemost. 69:1993;655.
72. WALENGA J.M., FAREED J. Relative contribution of factor Xa and factor IIa inhibition in the mediation of the antithrombotic actions of LMWHs and synthetic heparin pentasaccharides. Thromb Haemorr Dis. 3:1991;53-59.
73. OFOSU F.A., CHOAY J., ANVARI N., SMITH L.M., BLAJCHMAN M.A. Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma. Eur J Biochem. 193:1990;485-493.
74. BÉGUIN S., CHOAY J., HEMKER H.C. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost. 61:1989;397-401.
75. LORMEAU J.C., HERAULT J.P. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin, and a synthetic AT-III binding pentasaccharide. Thromb Haemost. 69:1993;152-156.
76. OFOSU F.A. Modulation of the enzymatic activity of α-thrombin by polyanions: Consequences on intrinsic activation of factor V and factor VIII. Haemostasis. 21:1991;240-247.
77. WUN T.-C. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: Synergistic anticoagulant action between LACI and sulfated polysaccharides. Blood. 79:1992;430-438.
78. JESKE, W. Doctoral thesis: Pharmacologic studies on synthetic analogues of heparin with selective affinity to endogenous serine protease inhibitors. Loyola University Chicago, Chicago, IL, May 1996.
79. RAO L.V.M., RAPAPORT S.I., HOANG A.D. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood. 81:1993;2600-2607.
80. OFOSU F.A., LECLERC J., DELORME F., CRAVEN S., SHAFAI S., FREWIN L., BLAJCHMAN M.A. The low molecular weight heparin enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery. Br J Haematol. 83:1992;391-399.
81. GEROTZIAFAS G.T., BARA L., BLOCH M.F., MAKRIS P.E., SAMAMA M.M. Treatment with LMWHs inhibits factor VIIa generation during in vitro coagulation of whole blood. Thromb Res. 81:1996;491-496.
82. LORMEAU J.C., HERAULT J.P., HERBERT J.M. Antithrombin mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to AT. Thromb Haemost. 76:1996;5-8.
83. BROZE G.J., WARREN L.P., NOVOTNY W.F., HIGUCHI D.A., GIRARD J.J., MILETICH J.P. Lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood. 71:1988;335-343.
84. JESTY J., LORENZ A., RODRIGUEZ J., WUN T-C. Initiation of the tissue factor pathway of coagulation in the presence of heparin: Control by antithrombin III and tissue factor pathway inhibitor. Blood. 87:1996;2301-2307.
85. HOPPENSTEADT D., WALENGA J.M., FASANELLA A., JESKE W., FAREED J. TFPI antigen levels in normal human volunteers after IV and SC administration of heparin and a low molecular weight heparin. Thromb Res. 77:1994;175-185.
86. BARA L., BLOCH M.F., ZITOUN D., SAMAMA M., COLLIGNON F., FRYDMAN A., UZAN A., BOUTHIER J. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res. 69:1993;443-452.
87. LINDAHL, A.K., SANDSET, P.M. and ABILDGAARD, U. The present status of tissue factor pathway inhibitor. Blood Coag Fibrinol 3, 439-49, 1992.
88. WUN T.C. Lipoprotein associated coagulation inhibitor (LACI) is a cofactor for heparin: Synergistic anticoagulant action between LACI and sulfated polysaccharides. Blood. 79:1992;430-438.
89. ZITOUN D., BARA L., BLOCH M.F., SAMAMA M.M. Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits. Thromb Res. 75:1994;577-580.
90. LOJEWSKI B., BACHER P., JESKE W., FAREED J. Molecular weight dependence on the release of tissue factor pathway inhibitor after subcutaneous and intravenous actions of heparins. Thromb Haemost. 69:1993;1174.
91. KAISER B., HOPPENSTEADT D.A., JESKE W., WUN T.C., FAREED J. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro-modulatory action of glycosaminoglycans. Thromb Res. 75:1994;609-616.
92. BERNAT A., HOFFMANN P., SAINTE-MARIE M., HERBERT J.M. The synthetic pentasaccharide SR 90107A/Org 31540 enhances tissue-type plasminogen activator-induced thrombolysis in rabbits. Fibrinolysis. 10:1996;151-157.
93. KAISER B., FAREED J. Effect of unfractionated heparin and a heparin pentasaccharide on the thrombolytic process in an experimental model in rabbits. Fibrinolysis. 10(Suppl 3):1996;127.
94. FAREED, J., HOPPENSTEADT, D., JESKE, W. and WALENGA, J.M. An overview of nonheparin glycosaminoglycans as antithrombotic agents. In: Recent Advances in Blood Coagulation. L. Poller (ed.), pp. 169-187, Churchill Livingstone, London (1993).
95. SALZMAN E.W., ROSENBERG R.D., SMITH M.H., LINDON J.N., FAVREAU L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest. 65:1980;64-73.
96. LABROUCHE S., FREYBURGER G., BELLOC F., BOISSEAU M.R. Influence of selected heparins on human neutrophil functions in vitro. Thromb Haemost. 68:1992;556-562.
97. WALLIS D.E., LEWIS B.E., PIFARRÉ R., SCANLON P.J. Active surveillance for heparin-induced thrombocytopenia or thromboembolism. Chest. 106:1994;120S.
98. BRACE L.D., FAREED J. Heparin-induced platelet aggregation: Dose/response relationships for a low molecular weight heparin derivative (PK 10169) and its subfractions. Thromb Res. 42:1986;769-782.
99. MESSMORE H.L., GRIFFIN B., FAREED J., COYNE E., SEGHATCHIAN J. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets. Ann NY Acad Sci. 556:1989;217-231.
100. WALENGA J.M., KOZA M.J., LEWIS B.E., PIFARRÉ R. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb/Hemostasis. 2(Suppl 1):1996;S21-S27.
101. ELALAMY I., LECRUBIER C., POTEVIN F., ABDELOUAHED M., BARA L., MARIE J.P., SAMAMA M. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin dependent factor of twenty-five patients with heparin associated thrombocytopenia. Thromb Haemost. 74:1995;1384-1385.
102. GREINACHER A., ALBAN S., DUMMEL V., FRANZ G., MUELLER-ECKHARDT C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost. 74:1995;886-892.
103. PIFARRÉ R., WALENGA J.M., KOZA M.J., KHENKINA Y., FAREED J. Comparative heparin induced thrombocytopenic response with low molecular weight heparin and a synthetic pentasaccharide. Thromb Haemost. 69:1993;1319.
104. JESKE W., SZATKOWSKI E., HOPPENSTEADT D., WALENGA J.M. Development of a flow cytometric assay for the detection of heparin induced thrombocytopenia. Blood. 88(Suppl 1):1996;317a.
105. WESSLER S., REIMER S.M., SHEPS M.C. Biologic assay of a thrombosis-inducing activity in human serum. J Appl Physiol. 14:1959;943-946.
106. WALENGA J.M., FAREED J., PETITOU M., SAMAMA M., LORMEAU J.C., CHOAY J. Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model. Thromb Res. 43:1986;243-248.
107. THOMAS D.P., MERTON R.E., GRAY E., BARROWCLIFFE T.W. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model. Thromb Haemost. 61:1989;204-207.
108. AMAR J., CARANOBE P., SIE P., BONEU B. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities: An experimental study in two models of thrombosis in the rabbit. Br J Haematol. 76:1990;94-100.
109. HOBBELEN P.M.J., VAN DINTHER T.G., VOGEL G.M.T., VAN BOECKEL C.A.A., MOELKER H.C.T., MEULEMAN D.G. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb Haemost. 63:1990;265-270.
110. BUCHANAN M.R., BONEU B., OFOSU F., HIRSH J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood. 65:1985;198-201.
111. CADE J.F., BUCHANAN M.R., BONEU B., OCKELFORD P., CARTER C.J., CERSKUS A.L., HIRSH J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation. Thromb Res. 35:1985;613-625.
112. BERGQVIST D., NILSSON B., HEDNER U., PEDERSEN P.C., OSTERGAARD P.B. The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis. Thromb Res. 38:1985;589-601.
113. RAAKE W., ELLING H. Rat jugular vein hemostasis - A new model for testing antithrombotic agents. Thromb Res. 53:1989;73-77.
114. VOGEL G.M.T., MEULEMAN D.G., BOURGONDIEN F.G.M., HOBBELEN P.M.J. Comparison of two experimental thrombosis models in rats, effects of four glycosaminoglycans. Thromb Res. 54:1989;399-410.
115. VOGEL G.M.T., VAN AMSTERDAM R.G.M., KOP W.J., MEULEMAN D.G. Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt. Thromb Haemost. 69:1993;29-34.
116. WEICHERT W., BREDDIN H.K. Effect of low molecular weight heparins on laser-induced thrombus formation in rat mesenteric vessels. Haemostasis. 18(Suppl 3):1988;55-63.
117. BERNAT A., HERBERT J.M. Protamine sulfate inhibits pentasaccharide (SR 80027)-induced bleeding without affecting its antithrombotic and anti-factor Xa activity in the rat. Haemostasis. 26:1996;195-202.
118. RACANELLI, A. Doctoral thesis: Biochemical and pharmacological studies on the interactions of protamine with heparins. Loyola University Chicago, Chicago, IL, January 1990.
119. YOUNG E., WELLS P., HOLLOWAY S., WEITZ J., HIRSH J. Ex-vivo and in vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost. 71:1994;300-304.
120. BACHER P., FAREED J., HOPPENSTEADT D., WALENGA J.M., IQBAL O. Endogenous AT III as a limiting factor in the mediation of antiprotease actions of heparins and related oligosaccharides. Impact on the pharmacodynamic parameters as calculated by using functional methods. Thromb Haemost. 65:1991;932.
121. CRÉPON B., DONAT F., BARZU T., HÉRAULT J.P. Pharmacokinetic (PK) parameters of AT binding pentasaccharides in three animal species: Predictive value for humans. Thromb Haemost. 69:1993;654.
122. HARA T., YOKOYAMA A., ISHIHARA H., YOKOYAMA Y., NAGAHARA T., IWAMOTO M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor of factor Xa. Thromb Haemost. 71:1994;314-319.
123. OSTREM J.A., STRINGER S., AL-OBEIDI F., SAFAR P., SAFAROVA A., LOCASCIO J.C., SPOONAMORE J., KASIREDDY P., THORPE D.S., SELIGMANN B.E., SEPETOV K., STROP P., WILDGOOSE P. Characterization of an orally available and highly specific synthetic factor Xa inhibitor. Thromb Haemost. 73:1995;1306.
124. GIRARD T.J., WARREN L.A., NOVOTNY W.F., LIKERT K.M., BROWN S.G., MILETICH J.P., BROZE G.J. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature. 338:1989;518-520.
125. HUANG Z.F., WUN T.C., BROZE G.J. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem. 268:1993;26950-26955.
126. DUNWIDDIE C., THORNBERRY N.A., BULL H.G., SARDANA M., FRIEDMAN P.A., JACOBS J.W., SIMPSON E. Antistasin, a leech-derived inhibitor of factor Xa. J Biol Chem. 264:1989;16694-16699.
127. TUSZYNSKI G.P., GASIC T.B., GASIC G.J. Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation. J Biol Chem. 262:1987;9718-9723.
128. VLASUK G.P., RAMJIT D., FUJITA T., DUNWIDDIE C.T., NUTT E.M., SMITH D.E., SHEBUSKI R.J. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost. 65:1991;257-262.
129. RAGOSTA M., GIMPLE L.W., GERTZ S.D., DUNWIDDIE C.T., VLASUK G.P., HABER H.L., POWERS E.R., ROBERTS W.C., SAREMBOCK I.J. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 89:1994;1262-1271.
130. THEUNISSEN H.J., DIJKEMA R., SWINKELS J.C., DE POORTER T.L., VINK P.M., VAN DINTHER T.G. Mutational analysis of antistasin, an inhibitor of blood coagulation factor Xa from the Mexican leech Haementeria officinalis. Thromb Res. 75:1994;41-50.
131. FAREED, J. Basic and applied pharmacology of low molecular weight heparins. Pharmacy Therapeut June, 16s-24s, 1995.
132. FAREED J., WALENGA J.M., HOPPENSTEADT D., HUAN X.O., NONN R. Biochemical and pharmacological inequivalence of low molecular weight heparins. Proc Natl Acad Sci USA. 556:1989;333-353.
133. CARRIE D., CARANOBE C., SALVIN S., HOUIN G., PETITOU M., LORMEAU J.C., VAN BOECKEL C., MEULEMAN D., BONEU B. Pharmacokinetic and pharmacodynamic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: Comparison with CY216. Blood. 84:1994;2571-2577.
134. BOCK S.C., HARRIS J.F., SCHWARTZ C.E., WARD J.H., HERSHGOLD E.J., SKOLNICK M.H. Hereditary thrombosis in a Utah kindred is caused by a dysfunctional antithrombin III gene. Am J Hum Genet. 37:1985;32-41.
135. BORG J.Y., OWEN M.C., SORIA C., CAEN J., CARRELL R.W. Proposed heparin binding site in antithrombin based on arginine 47. J Clin Invest. 81:1988;1292-1296.
136. CHANG J.Y., TRAN T.H. Antithrombin III Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity. J Biol Chem. 261:1986;1174-1176.
137. ERDJUMENT H., LANE D.A., PANICO M., DIMARZO V., MORRIS H.R. Single amino acid substitutions in the reactive site of antithrombin leading to thrombosis. Congenital substitution of arginine 393 to cysteine in antithrombin Northwick Park and to histidine in antithrombin Glasgow. J Biol Chem. 263:1988;5589-5593.
138. MILLE B., WATTON J., BARROWCLIFFE T., MANI J.C., LANE D. Role of N- and C-terminal aminoacids in antithrombin binding to pentasaccharide. J Biol Chem. 269:1994;29435-29443.
139. OLSON S.T., FRANCIS A.M., SHEFFER R., CHOAY J. Parallel mechanisms of high molecular weight kininogen action as a cofactor in kallikrein inactivation and prekallikrein activation reactions. Biochemistry. 32:1993;12148-12159.
140. LINDAHL U., LIDHOLT K., SPILLMANN D., KJELLÉN L. More to "heparin" than anticoagulation. Thromb Res. 75:1994;1-32.
141. VISSER A., MEULEMAN D.G. Inhibition of the early stages of the thrombin generation reaction by various glycosaminoglycans. Thromb Res. 58:1990;469-474.